Lipid Supplements

Lipid Supplements is a opaque white emulsion of fractionated soybeans oil in water produces using 1.2% fractionated egg yolk phospholipids. Glycerol is also present. These substances are source of energy and essential fatty acids.

Lipid Supplements is primarily indicated in conditions like Amino acid deficiency, Energy depletion, Energy source.

Lipid Supplements is contraindicated in conditions like Pregnancy, Lactation.

The severe or irreversible adverse effects of Lipid Supplements, which give rise to further complications include Hepatic damage, Thrombocytopenia, Hyperlipidemic effects, GI intolerance, Spontaneous bleeding, Hepatosplenomegaly, Lipid deposition. The symptomatic adverse reactions produced by Lipid Supplements are more or less tolerable and if they become severe, they can be treated symptomatically, these include Chills, Eosinophilia, Sensation of warmth.

Kabiven is hypertonic and may cause vein irritation, vein damage and even thrombosis if infused in a peripheral vein. Only infuse Kabiven into a central vein. Monitor for signs or symptoms of hypersensitivity reactions and discontinue infusion if reactions occur. Monitor patient closely for signs and symptoms of infection, hypertriglyceridemia, hyperglycemia and refeeding complications. Monitor laboratory parameters for alterations in electrolytes, liver and renal impairment, fluid status and coagulation parameters. Adjust rate and dose of Kabiven and Perikabiven according to clinical status. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance & Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see full Prescribing Information, including Boxed Warning, for Kabiven and Perikabiven.

Kabiven is hypertonic and may cause vein irritation, vein damage and even thrombosis if infused in a peripheral vein. Only infuse Kabiven into a central vein. Monitor for signs or symptoms of hypersensitivity reactions and discontinue infusion if reactions occur. Monitor patient closely for signs and symptoms of infection, hypertriglyceridemia, hyperglycemia and refeeding complications. Monitor laboratory parameters for alterations in electrolytes, liver and renal impairment, fluid status and coagulation parameters. Adjust rate and dose of Kabiven and Perikabiven according to clinical status. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance & Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see full Prescribing Information, including Boxed Warning, for Kabiven and Perikabiven.

1.428 to 3.214 mg/kg.min (2.3 (2.321)) As recommended. IV Inf — As Required

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Lipid Supplements was found.

Emulsion Store Between 15°C-30°C. Do not Freeze.